Cellectar Biosciences (CLRB) Enterprise Value (2010 - 2026)
Cellectar Biosciences (CLRB) posted Enterprise Value of -$13.2 million for Q4 2025, down 5.11% sequentially from -$12.6 million in Q3 2025, and up 43.34% YoY from -$9.2 million in Q4 2024.
Cellectar Biosciences (CLRB) Enterprise Value (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Enterprise Value for 16 years, with the latest figure at -$13.2 million in Q4 2025.
- Quarterly Enterprise Value rose 43.34% year-over-year to -$13.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.2 million (up 43.34% YoY) and the FY2025 annual result came in at -$13.2 million, up 43.34% from the prior year.
- Enterprise Value declined to -$13.2 million in Q4 2025 per CLRB's latest filing, from -$12.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.2 million in Q2 2023 and troughed at -$53.6 million in Q1 2021.
- A 5-year average of -$24.5 million and a median of -$21.6 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2023: Enterprise Value slumped 656.15% in 2021, then jumped 79.23% in 2023.
- Over 5 years, Enterprise Value stood at -$35.7 million in 2021, then soared by 44.36% to -$19.9 million in 2022, then jumped by 51.85% to -$9.6 million in 2023, then plunged by 143.48% to -$23.3 million in 2024, then surged by 43.34% to -$13.2 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$13.2 million, -$12.6 million, and -$11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | -33.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.99 Mn |
| Dec 31, 2025 | -13.20 Mn |
| Sep 30, 2025 | -12.55 Mn |
| Jun 30, 2025 | -11.04 Mn |
| Mar 31, 2025 | -13.91 Mn |
| Dec 31, 2024 | -23.29 Mn |
| Sep 30, 2024 | -34.26 Mn |
| Jun 30, 2024 | -25.87 Mn |
| Mar 31, 2024 | -40.03 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -18.99 Mn |
| Jun 30, 2023 | -5.15 Mn |
| Mar 31, 2023 | -12.68 Mn |
| Dec 31, 2022 | -19.87 Mn |
| Sep 30, 2022 | -17.79 Mn |
| Jun 30, 2022 | -24.81 Mn |
| Mar 31, 2022 | -30.63 Mn |
| Dec 31, 2021 | -35.70 Mn |
| Sep 30, 2021 | -40.34 Mn |
| Jun 30, 2021 | -46.78 Mn |